Actinium Pharmaceuticals, Inc. (ATNM)
1.05
-0.02
(-1.87%)
USD |
NYAM |
Nov 20, 16:00
1.06
+0.01
(+0.95%)
After-Hours: 20:00
Actinium Pharmaceuticals Enterprise Value : 5.494M for Nov. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2026 | 5.494M |
| November 19, 2026 | 6.123M |
| November 18, 2026 | 6.438M |
| November 17, 2026 | 14.93M |
| November 16, 2026 | 19.33M |
| November 13, 2026 | 24.04M |
| November 12, 2026 | 22.47M |
| November 11, 2026 | 22.47M |
| November 10, 2026 | 21.84M |
| November 09, 2026 | 20.90M |
| November 06, 2026 | 17.44M |
| November 05, 2026 | 13.35M |
| November 04, 2026 | 16.81M |
| November 03, 2026 | 16.50M |
| November 02, 2026 | 17.44M |
| October 30, 2026 | 19.01M |
| October 29, 2026 | 20.59M |
| October 28, 2026 | 15.87M |
| October 27, 2026 | 17.13M |
| October 26, 2026 | 16.50M |
| October 23, 2026 | 20.27M |
| October 22, 2026 | 22.79M |
| October 21, 2026 | 15.87M |
| October 20, 2026 | 16.50M |
| October 19, 2026 | 13.98M |
| Date | Value |
|---|---|
| October 16, 2026 | 8.010M |
| October 15, 2026 | 5.809M |
| October 14, 2026 | 3.124M |
| October 13, 2026 | 3.907M |
| October 12, 2026 | 5.809M |
| October 09, 2026 | 7.066M |
| October 08, 2026 | 6.438M |
| October 07, 2026 | 6.123M |
| October 06, 2026 | 7.381M |
| October 05, 2026 | 10.21M |
| October 02, 2026 | 9.267M |
| October 01, 2026 | 8.639M |
| September 30, 2026 | 7.695M |
| September 29, 2026 | 0.7112M |
| September 28, 2026 | 1.969M |
| September 25, 2026 | 2.598M |
| September 24, 2026 | 2.283M |
| September 23, 2026 | 1.969M |
| September 22, 2026 | 1.654M |
| September 21, 2026 | 2.598M |
| September 18, 2026 | 3.226M |
| September 17, 2026 | 2.283M |
| September 16, 2026 | 3.855M |
| September 15, 2026 | 4.170M |
| September 14, 2026 | 5.113M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.052B |
| Alnylam Pharmaceuticals, Inc. | 18.66B |
| Anika Therapeutics, Inc. | 158.39M |
| Savara, Inc. | 776.30M |
| Arrowhead Pharmaceuticals, Inc. | 6.053B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.843M |
| Total Expenses (Quarterly) | 5.843M |
| EPS Diluted (Quarterly) | -0.1858 |
| Earnings Yield | 31.94% |
| Operating Earnings Yield | 27.75% |
| Normalized Earnings Yield | 31.94 |